IndustryCompany release

10x Genomics lifts 2026 revenue guidance as Atera begins global shipments

🇺🇸 10x Genomics, Inc. (TXG) · Thu 05 Nov 2026

The single-cell and spatial biology company reported 1% third-quarter revenue growth to $150.7 million and a narrower net loss, while launching a new cloud analysis platform.

10x Genomics reported third-quarter 2026 revenue of $150.7 million on 5 November, up 1% on the same period a year earlier. Gross margin came in at 75%, and the company posted a net loss of $19.4 million, narrower than its loss a year before.

The company said it has started global commercial shipments of its Atera platform. It also introduced Sentira, a cloud-based analysis platform. The summary available does not give technical specifications, pricing or customer details for either product.

On the strength of the quarter, 10x Genomics raised its full-year 2026 revenue guidance to a range of $625 million to $635 million. The prior range was not included in the information available.

Cash and marketable securities stood at $575.7 million at the end of the quarter.

What it means for your team

  • Teams that rely on single-cell or spatial biology tools should note that Atera is now shipping globally, which may affect platform evaluation and procurement planning.
  • The Sentira cloud analysis platform may prompt data-handling and software validation questions for groups using it in regulated or quality-controlled workflows; no details on this were provided.
  • The raised guidance and a cash position of $575.7 million point to continued supplier stability for research-tool purchasers, though this is not investment advice.

Company's press release (SEC filing): 10x Genomics, Inc. ↗

Article written by VigiEye from the official source (10x Genomics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →